Evidence map›Paper›PMID 31748500›Full record

ArticleCell death & disease2019

Upregulation of IGF2R evades lysosomal dysfunction-induced apoptosis of cervical cancer cells via transport of cathepsins.

Takashi Takeda, Masayuki Komatsu, Fumiko Chiwaki, Rie Komatsuzaki, Kanako Nakamura, Kosuke Tsuji, Yusuke Kobayashi, Eiichiro Tominaga, Masaya Ono, Kouji Banno and 2 more

Open access · goldAbstract read
In one paragraph

Article in Cell death & disease, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed, 1 pooled it
2.2field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

42 citing papers in PubMed, 1 synthesis or guideline pooled it, 57 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Hepatocellular carcinoma: signaling pathways and therapeutic advances.Signal transduction and targeted therapy · 2025
    Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 2 countries.

Takashi TakedaDepartment of Translational Oncology, National Cancer Center Research Institute, Tokyo, 104-0045, Japan.ORCID http://orcid.org/0000-0001-6686-5742
Masayuki KomatsuDepartment of Translational Oncology, National Cancer Center Research Institute, Tokyo, 104-0045, Japan. makomats@ncc.go.jp.
Fumiko ChiwakiDepartment of Translational Oncology, National Cancer Center Research Institute, Tokyo, 104-0045, Japan.
Rie KomatsuzakiDepartment of Translational Oncology, National Cancer Center Research Institute, Tokyo, 104-0045, Japan.
Kanako NakamuraDepartment of Obstetrics and Gynecology, Keio University School of Medicine, Tokyo, 160-8582, Japan.
Kosuke TsujiDepartment of Obstetrics and Gynecology, Keio University School of Medicine, Tokyo, 160-8582, Japan.
Yusuke KobayashiDepartment of Obstetrics and Gynecology, Keio University School of Medicine, Tokyo, 160-8582, Japan.
Eiichiro TominagaDepartment of Obstetrics and Gynecology, Keio University School of Medicine, Tokyo, 160-8582, Japan.
Masaya OnoDepartment of Clinical Proteomics, National Cancer Center Research Institute, Tokyo, 104-0045, Japan.
Kouji BannoDepartment of Obstetrics and Gynecology, Keio University School of Medicine, Tokyo, 160-8582, Japan.
Daisuke AokiDepartment of Obstetrics and Gynecology, Keio University School of Medicine, Tokyo, 160-8582, Japan.
Hiroki SasakiDepartment of Translational Oncology, National Cancer Center Research Institute, Tokyo, 104-0045, Japan. hksasaki@ncc.go.jp.
Keio University · JPNational Cancer Research Institute · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cervical cancer is the most common gynecological malignancy in the world; however, the survival rates of advanced-stage and recurrent cervical cancer patients remain poor. The multifaced protein insulin-like growth factor 2 receptor (IGF2R) has various ligands, represented as IGF-2 and mannose-6-phosphate (M6P)-tagged proteins. Regarding its antagonistic activity as an IGF1R signal, IGF2R is currently considered a tumor suppressor gene, whereas its significance as an M6P receptor is still unclear. Here, on the basis of transcriptome analysis of TCGA and GEO open datasets, we show that IGF2R is upregulated and correlated with poor prognosis in cervical cancer. Several experiments using cervical cancer cell lines revealed that IGF2R depletion induced apoptosis, decreased cell viability, and increased vulnerability to certain anticancer drug cisplatin. In contrast to its negligible impact in IGF1R signaling, loss of IGF2R disrupted the Golgi-to-lysosome transport of M6P-tagged cathepsins, resulting in decreased lysosomal activity, with their abnormal accumulation and dysfunction of both autophagy and mitophagy, which cause the accumulation of misfolded proteins and production of reactive oxygen species. Taken together, IGF2R has an oncogenic role through transportation of M6P-tagged cargo in cervical cancer and can be used as a predictive biomarker for prognostic classification.

Indexed as

ApoptosisBiomarkers, TumorCathepsinsFemaleGene Knockdown TechniquesGolgi ApparatusHumansLysosomesMiddle AgedReactive Oxygen SpeciesReceptor, IGF Type 1Receptor, IGF Type 2RNA, MessengerUp-RegulationUterine Cervical NeoplasmsBiomarkers, TumorCathepsinsIGF1R protein, humanIGF2R protein, humanReactive Oxygen SpeciesReceptor, IGF Type 1Receptor, IGF Type 2RNA, Messenger

Identifiers

PMID31748500
PMCPMC6868013
OpenAlexW2991407782

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.